プロカルシトニン検査の世界市場 - 市場規模（セグメント別）、シェア、規制、償還、予測（～2033年）

当レポートでは、世界のプロカルシトニン検査市場について調査分析し、各セグメントの市場規模、市場動向、競合情勢、COVID-19の影響などの情報を提供しています。

市場モデルの主な内容は以下の通りです。

上市済みのプロカルシトニン検査と進化する競合情勢

• 主な業界動向の考察
• プロカルシトニン検査市場のセグメント別の年間収益と市場見通し（2015年～2033年）
• ユニット、平均販売価格、市場金額に関する市場レベルのデータ

世界、地域、国レベルの市場固有の考察

• 世界の動向を地域別に分類した定性的な市場固有の情報と国別の考察
• プロカルシトニン検査市場のSWOT分析
• プロカルシトニン検査市場の競合力学の考察と動向

医療制度の概要を含む真の全体像を把握することで、市場の理解を促進します。また、市場参入セグメントでは、償還政策や規制情勢についての情報を提供し、市場力学をより深く掘り下げることができます。

• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制情勢

対象企業

• Abbott Laboratories
• Thermo Fisher Scientific Inc
• Danaher Corp
• F. Hoffmann-La Roche Ltd
• DiaSorin SpA
• bioMerieux SA,Bio-Rad laboratories Inc
• Siemens AG
• Quidelortho Corp and Diazyme Laboratories Inc
• その他

Abstract

Procalcitonin Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Sepsis is a life-threatening condition characterized by organ dysfunction caused by a patient's dysregulated response to infection. Sepsis is related to but distinct from septicemia, which is the spread of bacterial infection through the bloodstream; sepsis is the dysregulated host response to that infection. Advanced sepsis is associated with a high mortality rate (20-30%) with contributing factors including late diagnosis, inappropriate clinical management, and suboptimal quality of care. The age distribution of those with sepsis is largely biphasic, affecting predominantly newborns (and their mothers) and the elderly; patients of an advanced age with sepsis tend to have a broad array of comorbidities. Sepsis can progress rapidly to a condition known as septic shock, where profound circulatory, cellular, and metabolic abnormalities present with a larger risk of mortality.

Procalcitonin testing provides a means for distinguishing bacterial from viral infection and monitoring the efficacy of antibiotic treatment. However, such tests are not used exclusively for sepsis patients. Procalcitonin may be used for patients with Lower Respiratory Tract Infections (LRTI), bacterial Pneumonia, or for monitoring potential infection of patients requiring mechanical ventilation. Respiratory infections including various pneumonia are the most common cause of sepsis, and ventilated patients may also be septic in addition to other comorbidities. Due to the non-mutually exclusive nature of these conditions, sepsis has been chosen as the primary disease state and indication for this market model. All other indications requiring procalcitonin testing are intended to be covered under "Other Indications" on each country tab within this model.

Procalcitonin Tests Model includes Procalcitonin Enzyme Immunoassay Tests and Procalcitonin Other Tests

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Procalcitonin Test and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Procalcitonin Tests market revenue by segment and market outlooks from

2015- 2033.

• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Procalcitonin Tests market.
• Competitive dynamics insights and trends provided for Procalcitonin Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific MedTech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, DiaSorin SpA, bioMerieux SA,Bio-Rad laboratories Inc, Siemens AG, Quidelortho Corp and Diazyme Laboratories Inc and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Procalcitonin Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Procalcitonin Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Procalcitonin Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Procalcitonin Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Procalcitonin Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.